A multivariable prognostic score to guide systemic therapy in early-stage HER2-positive breast cancer: a retrospective study with an external evaluation
Trastuzumab was administered intravenously every 3 weeks for 18 doses or weekly for 9 weeks. 5-year distant metastasis-free survival rates were 98% for low-risk, medium-risk, and high-risk patients. It could be used in the neoadjuvant setting, especially in the HER2-positive setting.
